Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

Overview of attention for article published in Lancet Oncology, February 2015

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (94th percentile)

Mentioned by

news: 6 news outlets
blogs: 3 blogs
policy: 2 policy sources
twitter: 27 X users

patent: 87 patents
facebook: 5 Facebook pages
f1000: 1 research highlight platform
guideline: 3 clinical guideline sources

Readers on

mendeley: 882 Mendeley

So far, Altmetric has seen 27 X posts from 27 X users, with an upper bound of 168,125 followers.

Hyper-progression looking like a major side effects for some immunotherapies https://t.co/ctEuPIcZoR

Activity/safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for ptns with advanced, refractory NSCLC https://t.co/J8twTNJr5T

Immune therapy (PD-1;nivolumab) produces prolonged response in ~10% of pretreated squamous #LungCancer patients http://t.co/n8wi1P64FP #lcsm

Promettenti risultati con anticorpi anti-PD1 nel tumore polmonare squamocellulare avanzato http://t.co/QDIK3FMu2Z

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 23 additional X posts.